Difference between revisions of "Safety/Policies"
| Line 30: | Line 30: | ||
<li> There will be no environmental release - This is existing iGEM policy for all projects and not just on gene drives.</li> | <li> There will be no environmental release - This is existing iGEM policy for all projects and not just on gene drives.</li> | ||
<li>That the project is safe - The Safety Committee will evaluate your project proposals with reference to host organism (chassis), modifications (including any associated parts) and containment measures. </li> | <li>That the project is safe - The Safety Committee will evaluate your project proposals with reference to host organism (chassis), modifications (including any associated parts) and containment measures. </li> | ||
| − | <li>Your team is implementing and adhering to the measures proposed by Akbari et al in “Safeguarding gene drive experiments in the laboratory” </li> | + | <li>Your team is implementing and adhering to the measures proposed by <a href="science.sciencemag.org/content/349/6251/927">Akbari et al</a> in “Safeguarding gene drive experiments in the laboratory” </li> |
<li>Your team has notified the Safety Committee that you are considering or planning to use gene drives in your project and you and your faculty advisor have participated in a mandatory conference call with experts on drives and on safeguards.</li> | <li>Your team has notified the Safety Committee that you are considering or planning to use gene drives in your project and you and your faculty advisor have participated in a mandatory conference call with experts on drives and on safeguards.</li> | ||
<li>Any orders for commercially produced genetic material placed by your team must be screened for regulated sequences.</li> | <li>Any orders for commercially produced genetic material placed by your team must be screened for regulated sequences.</li> | ||
| Line 51: | Line 51: | ||
<h2> Anti-microbial resistance (AMR) </h2> | <h2> Anti-microbial resistance (AMR) </h2> | ||
| − | <p>Resistance to important drugs is an increasing challenge to human and animal health. It has led to <a href="www.un.org/pga/71/event-latest/high-level-meeting-on-antimicrobial-resistance/"> high level discussions</a> at the United Nations General Assembly, a commitment to address this issue by world leaders and an action plan from the World Health Organization. As part of its commitment to safe and responsible research and innovation, iGEM has clarified its position on this important issue. </p> | + | <p>Resistance to important drugs is an increasing challenge to human and animal health. It has led to <a href="www.un.org/pga/71/event-latest/high-level-meeting-on-antimicrobial-resistance/"> high level discussions</a> at the United Nations General Assembly, a <a href="www.un.org/sustainabledevelopment/blog/2016/09/world-leaders-commit-to-act-on-antimicrobial-resistance/">commitment</a> to address this issue by world leaders and an <a href="www.who.int/antimicrobial-resistance/en/">action plan</a> from the World Health Organization. As part of its commitment to safe and responsible research and innovation, iGEM has clarified its position on this important issue. </p> |
<p> | <p> | ||
| − | iGEM recognises that some AMR-related sequences are common research tools and pose little public health risk. iGEM also realises that other AMR-related sequences could pose a public health risk. For example, the World Health Organization has identifies a series of Highest Priority Critically Important Antimicrobials and maintains a list of Critically Important Antimicrobials. As a result, iGEM will continue to accept AMR-related parts into the registry, but any part containing sequences connected to anti-microbial resistance not in common research use will be flagged. Such parts will not be included in the distribution kit and explicit permission for use from iGEM (via a check in form) will be required to get access to the part. To get permission, the Safety Committee will evaluate the project proposals with reference to host organism (chassis), modifications (including any associated parts) and containment measures. | + | iGEM recognises that some AMR-related sequences are common research tools and pose little public health risk. iGEM also realises that other AMR-related sequences could pose a public health risk. For example, the World Health Organization has identifies a series of <a href="www.who.int/foodsafety/cia/en/"> Highest Priority Critically Important Antimicrobials</a> and maintains a <a href="www.who.int/foodsafety/areas_work/antimicrobial-resistance/cia/en/">list of Critically Important Antimicrobials</a>. As a result, iGEM will continue to accept AMR-related parts into the registry, but any part containing sequences connected to anti-microbial resistance not in common research use will be flagged. Such parts will not be included in the distribution kit and explicit permission for use from iGEM (via a check in form) will be required to get access to the part. To get permission, the Safety Committee will evaluate the project proposals with reference to host organism (chassis), modifications (including any associated parts) and containment measures. |
</p> | </p> | ||
Revision as of 21:37, 6 January 2017
SAFETY POLICIES
As it is at the forefront of what is technologically possible, iGEM also comes across important policy issues on a continuing basis. In 2017 iGEM has clarified its positions on:
Gene drives
Policy discussions around gene drives center around whether they should be released into the environment and under what safety provisions should research be carried out. iGEM has a strict do no release policy – this applies to gene drives as well as any other projects. On the use of gene drives as research tools in iGEM projects, the policy is:
Gene Drives are not allowed in iGEM projects without a special exception from the Safety Committee.
Teams will need to convince the Safety Committee that:
- There will be no environmental release - This is existing iGEM policy for all projects and not just on gene drives.
- That the project is safe - The Safety Committee will evaluate your project proposals with reference to host organism (chassis), modifications (including any associated parts) and containment measures.
- Your team is implementing and adhering to the measures proposed by Akbari et al in “Safeguarding gene drive experiments in the laboratory”
- Your team has notified the Safety Committee that you are considering or planning to use gene drives in your project and you and your faculty advisor have participated in a mandatory conference call with experts on drives and on safeguards.
- Any orders for commercially produced genetic material placed by your team must be screened for regulated sequences.
- None of your parts submitted to the registry contain a functional gene drive – a drive in a single part will not be accepted and this can have implications for medal criteria.
For the purposes of iGEM, a gene drive includes Cas9 (and other endonucleases, such as dCas9 and Cpf1) integrated into the genome (including through the use of gRNA) of a sexually reproducing eukaryotic organisms (including organisms that reproduce both sexually and asexually, such as yeast) and/or the use of a drive to impact the progeny.
Anti-microbial resistance (AMR)
Resistance to important drugs is an increasing challenge to human and animal health. It has led to high level discussions at the United Nations General Assembly, a commitment to address this issue by world leaders and an action plan from the World Health Organization. As part of its commitment to safe and responsible research and innovation, iGEM has clarified its position on this important issue.
iGEM recognises that some AMR-related sequences are common research tools and pose little public health risk. iGEM also realises that other AMR-related sequences could pose a public health risk. For example, the World Health Organization has identifies a series of Highest Priority Critically Important Antimicrobials and maintains a list of Critically Important Antimicrobials. As a result, iGEM will continue to accept AMR-related parts into the registry, but any part containing sequences connected to anti-microbial resistance not in common research use will be flagged. Such parts will not be included in the distribution kit and explicit permission for use from iGEM (via a check in form) will be required to get access to the part. To get permission, the Safety Committee will evaluate the project proposals with reference to host organism (chassis), modifications (including any associated parts) and containment measures.
